Table 1 Mean growth inhibition (%) in primary CLL blasts.

From: Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies

Concentration (μM)

TL-895 (n = 21)

Ibrutinib (n = 21)

Acalabrutinib (n = 10)

25

90

97

80

5

72

76

64

1

61

63

56

0.2

53

57

47

0.04

50

47

40

0.008

43

43

34

  1. CLL chronic lymphocytic leukemia.
Back to article page